Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5209_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Preface
- •Contents
- •Contributors
- •Imaging
- •Personal Preference
- •Introduction
- •Traditional Radical Therapies
- •Active Surveillance
- •Why Consider Focal Therapy?
- •Cancer Treatment Needs
- •Functional Outcomes
- •Conclusion
- •Introduction
- •Focal Therapy Candidates
- •The Index Lesion Theory
- •Further Prospective
- •Conclusions
- •References
- •Introduction
- •Renal Mass Biopsy
- •Approach
- •Cryoablation
- •Treatment Temperature
- •Radiofrequency Ablation
- •Treatment Temperature
- •Intraoperative Monitoring
- •Cryoablation
- •Radiofrequency Ablation
- •Recommended Imaging Follow-Up Protocol
- •Emerging New Ablative Modalities
- •Microwave Ablation
- •Irreversible Electroporation
- •Radiation Therapy
- •Oncological Outcomes
- •Local Recurrence-Free Survival
- •Overall Survival
- •Cryoablation Versus Radiofrequency Ablation
- •Complications
- •Conclusion
- •References
- •Introduction
- •Informed Consent
- •Why Focal Therapy?
- •References
- •References
- •Introduction
- •Conclusions
- •References
- •Introduction
- •Conclusions
- •References
- •Introduction
- •Prostate MRI
- •Robotic Surgery
- •Conclusion
- •References
- •Introduction
- •References
- •Introduction
- •Conclusions
- •References
- •Decipher
- •Oncotype DX
- •Prolaris
- •Limitations
- •Conclusion
- •References
- •Background
- •Androgen Manipulation
- •Conclusion
- •References
- •Introduction
- •Genomic Biomarkers
- •Genomic Heterogeneity
- •Targeted Biopsy Outcomes
- •Outcomes After Active Surveillance
- •Outcomes After Radical Prostatectomy
- •Conclusions
- •References
- •Introduction
- •Early Prostate MRI Consensus Meetings
- •PI-RADS v2
- •PI-RADS v2.1
- •PI-RADS Vs. Likert Score
- •MRI-Targeted Biopsies
- •Reporting Cancer Recurrence
- •MRI After Focal Therapy
- •Conclusion
- •References
- •MR Segmentation
- •US Segmentation
- •MR-US Registration/Fusion
- •Conclusion
- •References
- •Introduction
- •Ultrasound Elastography
- •Strain Elastography
- •Shear Wave Elastography
- •Patient Factors During FB
- •Discussion
- •Learning Curve
- •Core Number Optimization
- •Transrectal Versus Transperineal
- •Future Directions
- •Acoustic Radiation Force Impulse (ARFI) Imaging
- •Quantitative Ultrasound
- •Micro-Ultrasound
- •Multiparametric Ultrasound
- •Conclusions
- •References
- •Multi-Parametric Magnetic Resonance Imaging
- •References
- •Introduction
- •Cognitive Fusion
- •In-Bore MRI-Guided Biopsy
- •Software-Based Image Coregistration
- •Registration Algorithms
- •Biopsy Needle Tracking
- •Biopsy Approach
- •Commercial Systems
- •Electromagnetic Tracking
- •Mechanical Position Encoders
- •Image-Based Tracking
- •Discussion
- •Conclusion
- •References
- •Introduction
- •Complications
- •Urinary Retention
- •Bleeding
- •Conclusion
- •References
- •Introduction
- •Institutional Examples
- •Setting
- •Results
- •Discussion
- •Summary
- •References
- •Introduction
- •PET-Guided Targeted Prostate Biopsy
- •Gallium-68 (68Ga)-Radiolabeled PSMA Ligands
- •Fluorine-18 (18F)-Radiolabeled PSMA Ligands
- •Gastrin-Releasing Peptide Receptor (GRPR)
- •Future Outlook
- •Conclusion
- •References
- •Introduction
- •Approach
- •Sampling
- •Core Length
- •Histologic Submission
- •BxChip™
- •Reporting Results
- •References
- •Introduction
- •Location: Treatment Factors
- •References
- •Introduction
- •Focal Therapy Nomenclature
- •Nerve-Sparing (Unilateral or Bilateral)
- •Hemi-Ablation
- •Anterior Hockey-Stick Ablation (Anterior Three-Fourth)
- •Posterior Hockey-Stick Ablation (Posterior Three-Fourth)
- •Targeted Focal Therapy
- •Quadrant (Zonal) Ablation
- •Conclusions
- •References
- •Introduction
- •Cryotherapy
- •Irreversible Electroporation (IRE)
- •Transurethral Ultrasound Ablation (TULSA)
- •High-Intensity Focused Ultrasound (HIFU)
- •Surgery (Partial Prostatectomy)
- •Evolving Frontiers
- •Conclusion
- •References
- •Background
- •Procedure Selection
- •Patients’ Selection
- •Anesthesia
- •Perioperative Protocols
- •Procedure
- •Postoperative Period
- •Outcomes
- •Procedure Feasibility
- •Adverse Events
- •Outcomes
- •Conclusion
- •References
- •Clinical Background
- •Radiotherapy Techniques
- •Clinical Evidence About High-Dose Rate Interventional Radiotherapy (HDR IRT)
- •Clinical Evidence About Low-Dose Rate Interventional Radiotherapy (LDR IRT)
- •Clinical Evidence About Focal External Beam Radiotherapy (ERT)
- •Discussion
- •References
- •28: Focal Cryotherapy
- •Introduction
- •Focal Cryotherapy Procedure
- •Contemporary Focal Cryotherapy Series
- •Primary Focal Cryoablation
- •Salvage Focal Cryotherapy
- •Surveillance
- •Future Developments
- •Imaging
- •Cryotechnology
- •Immune Enhancer
- •References
- •Background
- •Energy Principles: Basic Science
- •Conclusion
- •References
- •Introduction
- •Early Studies
- •Phase 1 Clinical Trial (“Subtotal” Ablation)
- •Phase II (“TACT”) Clinical Trial (“Whole Gland” Ablation)
- •Patient Selection
- •Preoperative Imaging Planning
- •Intraoperative Considerations
- •Follow-Up Routine Post-Focal TULSA
- •Summary
- •References
- •Vapor 1 Study Results
- •References
- •Introduction
- •Robotic HIFU
- •Safety Features
- •Robotic HIFU Procedure
- •Intraoperative Monitoring
- •Built-in Contrast-Enhanced Transrectal Ultrasound
- •Postoperative Care
- •Follow-up
- •Oncologic Outcomes
- •Functional Outcomes
- •Complications
- •Conclusions
- •References
- •Indications
- •Contraindications
- •Preprocedure Workup
- •Technique
- •Outcomes
- •Complications
- •Controversies
- •Conclusion
- •References
- •Introduction
- •Posttreatment MRI Findings
- •High-Intensity Focused Ultrasound (HIFU)
- •Focal Laser Ablation (FLA)
- •Irreversible Electroporation (IRE)
- •Focal Cryotherapy (FC)
- •Photodynamic Therapy (PDT)
- •Future Perspectives
- •Conclusion
- •References
- •Introduction
- •Oncological Outcomes
- •Biochemical Recurrence
- •Functional Outcomes
- •Perioperative Complications
- •Urinary
- •Sexual
- •Bowel
- •Decision Regret
- •Conclusion
- •References
- •36: Assessing Functional Outcomes After Focal Therapy
- •High-Intensity Focused Ultrasound (HIFU)
- •Cryotherapy
- •Irreversible Electroporation (IRE)
- •Focal Brachytherapy
- •Focal Laser Ablation (FLA)
- •Photodynamic Therapy (PDT)
- •Microwave Ablation
- •Partial Prostatectomy
- •Bipolar Radiofrequency Ablation (bRFA)
- •Prostatic Artery Embolization (PAE)
- •Urinary Function
- •IPSS
- •EPIC
- •ICIQ-SF
- •Erectile Function
- •IIEF
- •EPIC
- •Safety Outcomes
- •Clavien-Dindo
- •CTCAE
- •Physical/Mental Outcomes
- •SF-12
- •Monitoring Patients After Focal Therapy
- •References
- •Introduction
- •PSA Nadir
- •PSA Density
- •Other Molecular Biomarkers
- •Follow-Up Protocols After FT
- •References
- •Introduction
- •Postbrachytherapy Treatment Changes
- •Post High-Intensity Focused Ultrasound (HIFU) Treatment Changes
- •Post Cryotherapy Treatment Changes
- •Post Laser Ablation Changes
- •Post Photodynamic Therapy Changes
- •Post Irreversible Electroporation Changes
- •Interstitial Microwave Thermal Therapy
- •Radiofrequency Ablation
- •References
- •39: Salvage Treatment Following Focal Therapy
- •Introduction
- •Salvage Treatment Modalities
- •Repeat Ablation
- •Salvage Radical Treatment
- •Salvage Radical Prostatectomy
- •Salvage Radiotherapy
- •References
- •Introduction
- •Ensuring Appropriate Quality
- •Conclusion
- •References
- •Patient Selection
- •Posttreatment Follow-Up
- •Conclusions
- •References
- •Index

15 Employing aQuality Improvement Program toOptimize mpMRI-Directed Fusion Biopsy
161
algorithms is possible by retrospective assessment of the procedure based on the biopsy results
and trajectory of each needle relative to the target, which will be discussed below.
Patient Factors During FB
Noise-canceling headphones and relaxing music
have been suggested to alleviate anxiety and,
according to certain studies, can positively impact
(decrease) the perceived pain level [25, 26]. The
application of intrarectal topical anesthesia is
advantageous for pain management, although it
is less effective than periprostatic nerve block
while combining both modalities yields superior
outcomes in terms of pain control [27]. Apical
lesion targeting is challenging, and the operator
should maneuver the probe to ensure that the
needle insertion site is above the dentate line to
prevent patient movement due to pain.
Familiarizing the patient with the “snap” sound
of the biopsy device can prevent the startle movement of the patient during the procedure. Our
institutional study showed that the anxiety from
FB plus systematic biopsy is higher than the systematic biopsy alone, which could be attributed
to the relatively longer duration of FB or/and the
patient’s perceived knowledge of higher chances
of the csPCa detection by FB [28]. Thus, explaining what to expect on the biopsy date and continuous communication with the patient during
the procedure can minimize patient movements
and increase the chances of successful FB.
single-bevel needle tip gives a longer length of
tissue but has higher deection, the multi-bevel
design helps to balance bending moments but
decreases the length of the tissue sampling [29].
The operator must be familiar with the characteristics of the needle in use and make appropriate
adjustments to account for deection during the
targeting and ring processes.
Congurations of US probes, such as side-
ring or end-ring, exhibit comparable PCa
detection rates and are selected based on the
operator’s preference and target location [30, 31].
Based on our experience, using a side-ring conguration for apical lesions can spare the sphincter bers (which are located immediately anterior
to the apex) and avoid pain and the resultant
patient movement. Conversely, end-re needles
are more helpful when seminal vesicle FB is indicated (the following ndings increase the odds of
detection of seminal vesicle invasion on pathology: mpMRI suspicion for seminal vesicle
involvement, prostate base lesions with moderate
suspicion of extra-prostatic extension, postbiopsy high GG lesion at prostate base [32]).
Ideally, biopsy cores should be handled in a
separate container for each site. Submitting more
than two cores in a single container increases the
probability of tissue core fragmentation [33].
More details on biopsy core optimization are discussed in Chap. 22 of this textbook by Iczkowski.
Reverse Fusion Workow:
TheCrucial Element ofQI inFB
Obtaining theBiopsy
Precise navigation toward MRI targets involves
utilizing fusion software as a guiding tool, coupled with the simultaneous correlation of landmarks through real-time ultrasound. Following
successful fusion, rapid completion of the procedure is imperative to minimize patient discomfort. One of the factors that can alter FB precision
in hitting the target is the geometry of the biopsy
needle tip, which inuences both needle deection and the length of tissue sampling. While a
While reverse fusion serves as the concluding section of this chapter, it is the initiation of the learning process. In the case of a discordant biopsy, it
is not acceptable for the clinician to solely convey
a negative result to the patient without gaining a
deeper understanding of the potential factors contributing to the discordance. For proper patient
counseling, QI, and research purposes, it is crucial
to compare pre-biopsy imaging ndings with histopathological results, ensuring accurate diagnoses and facilitating learning from any potential
errors. As mentioned before, reverse fusion refers
to the multidisciplinary review of discordant

162
M. Mottaghi et al.
pathology results of FB by re-evaluation of imaging and lesion sampling. Namely, uncertainty
arises when the biopsy of PI-RADS 4/5 lesions
results in grade group (GG) 1 disease or benign
prostate instead of the expected diagnosis of
csPCa.
Our institutional ow of the reverse fusion
starts with a re-evaluation of the original mpMRI
by a fellowship-trained prostate radiologist with
over 13years of experience (the corresponding
author of the present chapter). This step aims to
afrm or downgrade the assigned PI-RADS
score. If the second radiologist conrms the initial PI-RADS score, the discordant results are
considered unresolved. Discordance is considered resolved if the imaging review conrms a
PI-RADS of 3 or lower. The second step involves
an assessment of sufcient sampling by a minimum of two cores per target. As mentioned
before, several fusion platforms can record ultrasound segmentation, US-MRI registration and
fusion, and needle trajectories. Reviewing these
steps is essential to detect any procedural error
that could potentially cause discordant results.
Such multidisciplinary meetings also provide a
QI opportunity to evaluate radiology and pathology structured reports and facilitate the harmonization of terminology between different
disciplines [34]. An illustration of the approach
to discordant biopsy results is shown in Fig.15.4.
As a practical example, we used the presented
workow to assess discordant results of PI-RADS
4 lesions in our institution. After re-evaluation
through the motioned algorithm, we subcategorized those lesions based on the ADC
maps. From a total of 286 lesions, the subcategorization of lesions into higher suspicion (4-plus)
and lower suspicion (4-minus) yielded 158 and
117 lesions, respectively [35]. Reverse fusion
analysis demonstrated that 61% of 4-plus lesions
and 17% of 4-minus lesions contained csPCa
with signicantly different PSAD [median (IQR):
0.16 (0.1–0.2) versus 0.13 (0.08–0.2), respectively]. In another institutional example of 121
PI-RADS 5 lesions, we detected 45 discordant
results, out of which 27 were unresolved [5]. The
Fig. 15.4 Our institutional reverse fusion algorithm for
discordant pathology results. GGG: Gleason grade group;
PSA: prostate-specic antigen. (Reprinted from Kotamarti
S, Gupta RT, Wang B, Séguier D, Michael Z, Zhang D,
Abern MR, Huang J, Polascik TJ.Reconciling Discordance
Between Prostate Biopsy Histology and Magnetic
Resonance Imaging Suspicion - Implementation of a
Quality Improvement Protocol of Imaging Re-review and
Reverse fusion Target Analysis. Eur Urol Oncol. 2022
Oct;5(5):483–493 with permission from Elsevier)

15 Employing aQuality Improvement Program toOptimize mpMRI-Directed Fusion Biopsy
163
positive predictive value of PI-RADS 5 lesion in
detecting csPCa increased from 0.63 to 0.74
before and after adjusting for unresolved discordant results. To provide more detailed examples
of our QI protocol, a case series by Kotamarti
etal. discusses several examples from our institutional multidisciplinary experience of the reverse
fusion [36].
Discussion
Learning Curve
Although we present our institutional workow,
there are numerous potential areas for QI research
in optimizing FB.Commonly used types of MRIdirected prostate sampling are cognitive biopsy,
MRI-ultrasound software-fusion targeted biopsy
(FB), and in-bore MRI-guided biopsy; each technique possesses specic advantages and disadvantages in terms of cost, availability, required
equipment, learning curve, biopsy site recording,
operative time, the possibility of simultaneous
systematic biopsy, etc. The approach of these
biopsy techniques could be transrectal or transperineal [37]. The increased diagnostic quality of
prostate mpMRI has made targeted biopsy possible. Compared to standard systematic biopsy,
several well-designed studies have shown that FB
enables the detection of a greater number of clinically signicant PCa (csPCa) with fewer noncsPCa diagnoses [38, 39]. Following the
increasing adoption of FB, reports from pioneered centers with experienced urologists highlighted a signicant learning curve. One report
mentioned that after 1300 consecutive cases in a
4-year period, cancer detection rates continued to
increase, especially for lesions with PI-RADS ≥4
(with a detection rate of 50% in 2012 rising to
76% in 2016) [40, 41]. A recent study demonstrated that when a facility begins to adopt FB, a
prociency threshold to reach consistent, high
performance in csPCa detection rate was
observed after approximately 50 cases, indicating the learning curve for optimal implementation [41]. In addition to improved urologists’
technical skills, such increases in detection rate
likely reect institutional improvements in different disciplines like mpMRI interpretation and
reporting, MR-US co-registration, pathology
reporting, and interdisciplinary communication.
Core Number Optimization
The optimal number of targeted biopsy cores has
remained controversial. Based on the results of
the PRECISION trial, four cores per target are
superior to a 10–12 core TRUS-guided systematic biopsy [38]. In 2023, European Urological
Association [42] and American Urological
Association [43] guidelines advised combining
targeted biopsy with systematic biopsy for
biopsy-naïve patients with mpMRI-visible
lesions, necessitating greater numbers of biopsy
cores. This increases the complication rate (i.e.,
infection, bleeding, discomfort, and urinary
issues) as well as the time and expenses related to
the procedure and pathology study. Several studies tried to optimize MRI-FTB core numbers by
obtaining 1–5 cores from the target [44–46].
Although the rst two cores obtained from the
target diagnose the majority (75–89%) of the
csPCa, it has been shown to miss csPCa in
11–25% of cases, and additional cores up to 4–5
transrectal samples from the target could benet
this proportion of cases [47, 48].
Besides targeting the lesion or so-called
umbra, sampling of the 10-mm shadow or “penumbra” could improve the detection rate of
csPCa and decrease the detection of non-csPCa
[49]. A meta-analysis comparing the effective-
ness of MRI-FTB plus regional biopsy to MRIFTB plus systematic biopsy found signicant
heterogeneity in denitions for regional sampling, highlighting a lack of consensus for this
core number optimization efforts. Examples of
such denitions proposed for sampling the rest
of the prostate tissue are ipsilateral systematic
biopsy, regional saturation or targeted sampling
(cores taken in the 5-mm interval, along the longest axis of ROIs plus the adjacent cross-hair
pattern), focal saturation biopsy (cores taken
from the target sector and an adjacent sector),
and targeted sector sampling (cores taken from

164
M. Mottaghi et al.
the target sector) [50]. This meta-analysis study,
with overall 2600 MRI-positive cases, concluded that regional sampling (considering the
mentioned heterogeneity) could decrease the
number of cores by a median of 6.5 [IQR 4–16],
and cumulative detection rates of csPCa
(GG>1) were not inferior to FB plus systematic
biopsy [50].
Transrectal Versus Transperineal
A paradigm shift has been initiated in recent
years toward the TP approach, mainly with the
rationale of lower infectious complications and
better anterior PCa detection. In a multicenter,
randomized trial, Hu et al. allocated biopsynaïve participants to either undergo TP (287
cases) biopsy without antibiotic prophylaxis or
TR (280 cases) biopsy with targeted prophylaxis [51]. The latter involved rectal culture
screening for uoroquinolone- resistant bacteria,
with antibiotic administration tailored to the
culture and sensitivity results. Infectious and
non-infectious complications and csPCa detection rates were comparable. Mian etal. showed
the same infectious complications for the TP
approach without prophylaxis and the TR
approach with prophylaxis [52]. Although the
TP approach is preferred in terms of lower antibiotic use, antimicrobial resistance rates, and
urosepsis admissions, it is usually more timeconsuming and requires more staff, while the
physician’s reimbursement is not proportional
in the US health system. Additionally, based on
a survey in 2023, less than 50% of urology residents were exposed to TP biopsy, and lower
exposure inherently translates to lower intent to
adoption of TP biopsy post- training [53]. Some
argue that the increased infection from the TR
approach, although a higher form than that of
TP, is clinically low in experienced centers.
However, probably more detailed studies on
cost-effectiveness and the added benet of omitting antibiotic prophylaxis in this specic
patient population are needed for a more condent conclusion.
Future Directions
The most important requirement of an ideal FB is
accurate localization with an imaging modality
that is reproducible and has less operatordependent variation. This rapid and widespread
adoption of mpMRI for PCa management has
resulted in large volumes of mpMRI but not all of
this MRI demonstrates high image quality or
highly accurate image interpretation [54]. This
variability of quality poses a signicant risk as
producing diagnostic images of suboptimal quality could lead to downstream challenges in imagedirected biopsy or even biopsy being not
performed in cases where it should be performed.
Even when the quality is deemed acceptable, the
variety in equipment, practices, and image interpretation can complicate mpMRI standardization.
Studies have demonstrated that the PPVs for a
given PI-RADS score can vary not only among
different institutions but also among individual
radiologists [9, 55]. Some of these variations can
be attributed to factors such as the pretest probability of patients undergoing mpMRI and the
expertise of the radiologist. However, it should be
mentioned that protocols to obtain prostate MRI
can be heterogeneous worldwide and mostly set
based on each institution’s radiologists and physicists. Although PI-RADS v2.1 has provided the
minimum technical requirements for performing
prostate mpMRI (which are important to follow)
and systems such as Prostate Imaging Quality
(PI-QUAL) have attempted to standardize assessment of MR image quality, it is evident that even
adherence to these technical standards does not
ensure high quality, as certain MRI machines may
achieve better results with technical parameters
beyond the recommended guidelines [56]. This is
a huge opportunity for QI in imaging and, consequently, in FB to move toward a more standardized mpMRI where new technology such as deep
learning could be used to improve image quality,
reduce image acquisition time, and help to standardize the appearance of prostate MR images.
This will undoubtedly help in rectifying interreader discrepancies pave the way for articial
intelligence aided detection to become a reality.

15 Employing aQuality Improvement Program toOptimize mpMRI-Directed Fusion Biopsy
165
Conclusion
The workow for QI in FB underscores the critical importance of interdisciplinary communication among radiologists, urologists, and
pathologists. Inaccuracies in FB can stem from
the operator’s experience, inaccurate segmentation of the mpMRI and/or US, registration/fusion
errors, variations in prostate deformation due to
factors like the TRUS probe, patient positioning,
endorectal coil, rectal stool/gas content, bladder
fullness, errors in handling biopsy cores, etc. The
workow, as exemplied, follows a meticulous
process from MRI acquisition to biopsy, planning
sessions for mutual understanding, and continuous learning through routine reviews. Regular inperson multidisciplinary meetings enhance the
planning phase, aiming to establish consensus on
MRI targets and address discordant biopsy
results. In essence, the outlined institutional
example reects a commitment to QI at every
stage of the FB process, promoting effective
communication, learning, and adaptability for
better patient care.
References
1. Kelly AM, Cronin P. Practical approaches to quality improvement for radiologists. Radiographics.
2015;35(6):1630–42.
2. Tay KJ, Gupta RT, Rastinehad AR, Tsivian E,
Freedland SJ, Moul JW, Polascik TJ. Navigating
MRI-TRUS fusion biopsy: optimizing the process
and avoiding technical pitfalls. Expert Rev Anticancer
Ther. 2016;16(3):303–11.
3. University of Pennsylvania. MRI-ultrasound prostate fusion biopsy. https://www.pennmedicine.
org/for- patients- and- visitors/find- a- program- orservice/urology/male- urology- program/mri- fusionbiopsy#:~:text=The%20fusion%20biopsy%20
technology%20combines,tissue%20sample)%20
with%20a%20needle. Accessed 14 Feb 2024.
4. Kinnaird A, Sharma V, Chuang R, Priester A, Tran E,
Barsa DE, etal. Risk of prostate cancer after a negative magnetic resonance imaging guided biopsy. J
Urol. 2020;204(6):1180–6.
5. Arcot R, Sekar S, Kotamarti S, Krischak M, Michael
ZD, Foo W-C, etal. Structured approach to resolving discordance between PI-RADS v2. 1 score
and targeted prostate biopsy results: an opportunity for quality improvement. Abdom Radiol.
2022;47(8):2917–27.
6. Lin SL, Lin CT, Huang WT, Jou YC, Tzai TS, Tsai
YS. History of urinary retention is a risk factor
for infection after prostate biopsy: a nationwide,
population- based cohort study. Surg Infect (Larchmt).
2019;20(3):202–7.
7. Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH,
Mehralivand S, Gomella PT, et al. MRI-targeted,
systematic, and combined biopsy for prostate cancer
diagnosis. N Engl J Med. 2020;382(10):917–28.
8. Wei JT, Barocas D, Carlsson S, Coakley F,
Eggener S, Etzioni R, etal. Early detection of prostate cancer: AUA/SUO guideline (2023). J Urol.
2023;210(1):46–53.
9. Westphalen AC, McCulloch CE, Anaokar JM, Arora
S, Barashi NS, Barentsz JO, etal. Variability of the
positive predictive value of PI-RADS for prostate
MRI across 26 centers: experience of the society of
abdominal radiology prostate cancer disease-focused
panel. Radiology. 2020;296(1):76–84.
10. Westphalen AC, Fazel F, Nguyen H, Cabarrus
M, Hanley-Knutson K, Shinohara K, Carroll
PR. Detection of clinically signicant prostate cancer with PI-RADS v2 scores, PSA density, and ADC
values in regions with and without mpMRI visible
lesions. Int Braz J Urol. 2019;45:713–23.
11. Parekh S, Ratnani P, Falagario U, Lundon D, Kewlani
D, Nasri J, etal. The Mount Sinai Prebiopsy risk calculator for predicting any prostate cancer and clinically signicant prostate cancer: development of a
risk predictive tool and validation with advanced neural networking, prostate magnetic resonance imaging
outcome database, and European randomized study of
screening for prostate cancer risk calculator. Eur Urol
Open Sci. 2022;41:45–54.
12. Wang NN, Zhou SR, Chen L, Tibshirani R, Fan RE,
Ghanouni P, et al. The Stanford Prostate Cancer
Calculator: development and external validation of
online nomograms incorporating PIRADS scores
to predict clinically signicant prostate cancer. In:
Urologic oncology: seminars and original investigations. Amsterdam: Elsevier; 2021.
13. Frisbie JW, Van Besien AJ, Lee A, Xu L, Wang S,
Choksi A, et al. PSA density is complementary to
prostate MP-MRI PI-RADS scoring system for risk
stratication of clinically signicant prostate cancer.
Prostate Cancer Prostatic Dis. 2023;26(2):347–52.
14. Fang AM, Shumaker LA, Martin KD, Jackson JC,
Fan RE, Khajir G, etal. Multi-institutional analysis
of clinical and imaging risk factors for detecting clinically signicant prostate cancer in men with PI-RADS
3 lesions. Cancer. 2022;128(18):3287–96.
15. Kilic M, Madendere S, Vural M, Koseoglu E, Balbay
MD, Esen T.The role of the size and number of index
lesion in the diagnosis of clinically signicant prostate cancer in patients with PI-RADS 4 lesions who
underwent in-bore MRI-guided prostate biopsy.
World J Urol. 2023;41(2):449–54.
16. Lebastchi AH, O'Connor LP, Wang AZ, Yerram N,
Gurram S, Hale G, etal. Does size matter? Lesion size
as an indicator of number of cores needed to detect

166
M. Mottaghi et al.
clinically signicant prostate cancer. J Clin Oncol.
2020;38:283.
17. Soerensen SJC, Fan RE, Seetharaman A, Chen L,
Shao W, Bhattacharya I, etal. Deep learning improves
speed and accuracy of prostate gland segmentations
on magnetic resonance imaging for targeted biopsy. J
Urol. 2021;206(3):604–12.
18. Ghafoor S, Steinebrunner F, Stocker D, Hötker AM,
Schmid FA, Eberli D, Donati OF. Index lesion contouring on prostate MRI for targeted MRI/US fusion
biopsy—evaluation of mismatch between radiologists
and urologists. Eur J Radiol. 2023;162:110763.
19. Park JS, Lee D, Koo KC, Chung BH, Lee KS.The
role of prostatic apex shape in voiding symptoms and
urine ow: an exploratory and conrmatory study.
World J Urol. 2020;38(5):1275–82.
20. Qasim M, Puigjaner D, Herrero J, López JM, Olivé C,
Fortuny G, Garcia-Bennett J.Biomechanical modelling of the pelvic system: improving the accuracy of
the location of neoplasms in MRI-TRUS fusion prostate biopsy. BMC Cancer. 2022;22(1):338.
21. Ferriero M, Tuderti G, Muto GL, Fiori C, Bove AM,
Mastroianni R, et al. Diagnostic performance of
fusion (US/MRI guided) prostate biopsy: propensity
score matched comparison of elastic versus rigid
fusion system. World J Urol. 2022;40(4):991–6.
22. Venderink W, de Rooij M, Sedelaar JM, Huisman HJ,
Fütterer JJ.Elastic versus rigid image registration in
magnetic resonance imaging–transrectal ultrasound
fusion prostate biopsy: a systematic review and metaanalysis. Eur Urol Focus. 2018;4(2):219–27.
23. Hale GR, Czarniecki M, Cheng A, Bloom JB, Seifabadi
R, Gold SA, et al. Comparison of elastic and rigid
registration during magnetic resonance imaging/ultrasound fusion-guided prostate biopsy: a multi-operator
phantom study. J Urol. 2018;200(5):1114–21.
24. Klingebiel M, Arsov C, Ullrich T, Quentin M,
Al-Monajjed R, Mally D, etal. Reasons for missing
clinically signicant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided
biopsy. Eur J Radiol. 2021;137:109587.
25. Lee BC, Kim HO, Chung HS, Heo SH, Jeong YY,
Kim MS, et al. Does music from noise-canceling
headphones have a benecial effect on men undergoing transrectal ultrasound-guided prostate biopsy?
Prostate Int. 2021;9(3):145–50.
26. Tsivian M, Qi P, Kimura M, Chen VH, Chen SH, Gan
TJ, Polascik TJ.The effect of noise-cancelling headphones or music on pain perception and anxiety in
men undergoing transrectal prostate biopsy. Urology.
2012;79(1):32–6.
27. Yang Y, Liu Z, Wei Q, Cao D, Yang L, Zhu Y, etal.
The efciency and safety of Intrarectal topical anesthesia for Transrectal ultrasound-guided prostate
biopsy: a systematic review and meta-analysis. Urol
Int. 2017;99(4):373–83.
28. Deivasigamani S, Adams ES, Kotamarti S, Mottaghi
M, Taha T, Aminshari A, etal. Comparison of procedural anxiety and pain associated with conventional
transrectal ultrasound prostate biopsy to magnetic
resonance imaging-ultrasound fusion-guided biopsy:
a prospective cohort trial. Prostate Cancer Prostatic
Dis. 2024;27:294–9.
29. Li ADR, Plott J, Chen L, Montgomery JS, Shih
A. Needle deection and tissue sampling length
in needle biopsy. J Mech Behav Biomed Mater.
2020;104:103632.
30. van der Slot MA, Leijte JAP, van der Schoot DKE,
Oomens E, Roemeling S.End-re versus side-re: a
randomized controlled study of transrectal ultrasound
guided biopsies for prostate cancer detection. Scand J
Urol. 2020;54(2):101–4.
31. Hong CW, Rais-Bahrami S, Walton-Diaz A, Shakir
N, Su D, George AK, etal. Comparison of magnetic
resonance imaging and ultrasound (MRI-US) fusionguided prostate biopsies obtained from axial and sagittal approaches. BJU Int. 2015;115(5):772–9.
32. Gold SA, Shih JH, Rais-Bahrami S, Bloom JB,
Vourganti S, Singla N, etal. When to biopsy the seminal vesicles: a validated multiparametric magnetic
resonance imaging and target driven model to detect
seminal vesicle invasion of prostate cancer. J Urol.
2019;201(5):943–9.
33. Paner G, Srigley J, Pettus J, Giannico G, Sirintrapun
J, Harik L. Protocol for the examination of prostate
needle biopsies from patients with carcinoma of the
prostate gland: specimen level reporting. College of
American Pathologists: Northeld, MN; 2021.
34. Aminshari A, Gupta RT, Huang J, Polascik
TJ. Three- dimensional localization and targeting of
prostate cancer foci with imaging and histopathologic correlation: establishing a multidisciplinary
team for quality improvement. Curr Opin Urol.
2018;28(6):506–11.
35. Deivasigamani S, Kotamarti S, Adams ES, Séguier
D, Zhang D, Michael Z, et al. Reconciling discordance between PI-RADS 4 lesions and targeted
biopsy: early experience of a multidisciplinary quality
improvement protocol with PI-RADS 4 subcategorization. Eur J Radiol. 2023;165:110929.
36. Kotamarti S, Gupta RT, Wang B, Séguier D, Michael
Z, Zhang D, etal. Reconciling discordance between
prostate biopsy histology and magnetic resonance
imaging suspicion–implementation of a quality
improvement protocol of imaging re-review and
reverse-fusion target analysis. Eur Urol Oncol.
2022;5:483.
37. Chang SD, Ghai S, Kim CK, Oto A, Giganti F, Moore
CM. MRI targeted prostate biopsy techniques: AJR
expert panel narrative review. Am J Roentgenol.
2021;217(6):1263–81.
38. Kasivisvanathan V, Rannikko AS, Borghi M,
Panebianco V, Mynderse LA, Vaarala MH, etal. MRItargeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77.
39. Siddiqui MM, Rais-Bahrami S, Turkbey B, George
AK, Rothwax J, Shakir N, etal. Comparison of MR/
ultrasound fusion–guided biopsy with ultrasoundguided biopsy for the diagnosis of prostate cancer.
JAMA. 2015;313(4):390–7.

15 Employing aQuality Improvement Program toOptimize mpMRI-Directed Fusion Biopsy
167
40. Meng X, Rosenkrantz AB, Huang R, Deng F-M,
Wysock JS, Bjurlin MA, et al. The institutional
learning curve of magnetic resonance imagingultrasound fusion targeted prostate biopsy: temporal
improvements in cancer detection in 4 years. J Urol.
2018;200(5):1022–9.
41. Xu L, Ye NY, Lee A, Chopra J, Naslund M, WongYou- Cheong J, et al. Learning curve for magnetic
resonance imaging/ultrasound fusion prostate biopsy
in detecting prostate cancer using cumulative sum
analysis. Curr Urol. 2023;17(3):159–64.
42. Urology EAo. EAU-EANM-ESTRO-ESUR-ISUP- SIOG guidelines on prostate cancer. 2023.
43. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener
S, Etzioni R, et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a
prostate biopsy. J Urol. 2023;210(1):54–63.
44. Jiang X, Chen M, Tian J, Li X, Liu R, Wang Y,
et al. Comparison of regional saturation biopsy, targeted biopsy, and systematic biopsy in patients with
prostate- specic antigen levels of 4–20 ng/ml: a prospective, single-center, randomized controlled trial.
Eur Urol Oncol. 2023;7:944.
45. Calio BP, Sidana A, Sugano D, Gaur S, Maruf M,
Jain AL, etal. Risk of upgrading from prostate biopsy
to radical prostatectomy pathology-does saturation biopsy of index lesion during multiparametric
magnetic resonance imaging-Transrectal ultrasound
fusion biopsy help? J Urol. 2018;199(4):976–82.
46. Tracy CR, Flynn KJ, Sjoberg DD, Gellhaus PT, Metz
CM, Ehdaie B. Optimizing MRI-targeted prostate
biopsy: the diagnostic benet of additional targeted
biopsy cores. Urol Oncol. 2021;39(3):193.e1–6.
47. Kenigsberg AP, Renson A, Rosenkrantz AB, Huang
R, Wysock JS, Taneja SS, Bjurlin MA. Optimizing
the number of cores targeted during prostate magnetic
resonance imaging fusion target biopsy. Eur Urol
Oncol. 2018;1(5):418–25.
48. Lu AJ, Syed JS, Ghabili K, Hsiang WR, Nguyen
KA, Leapman MS, Sprenkle PC.Role of core number and location in targeted magnetic resonance
imaging-ultrasound fusion prostate biopsy. Eur Urol.
2019;76(1):14–7.
49. Brisbane WG, Priester AM, Ballon J, Kwan L, Deln
MK, Felker ER, et al. Targeted prostate biopsy:
umbra, penumbra, and value of perilesional sampling.
Eur Urol. 2022;82(3):303–10.
50. Hagens MJ, Fernandez Salamanca M, Padhani
AR, van Leeuwen PJ, van der Poel HG, Schoots
IG. Diagnostic performance of a magnetic resonance imaging-directed targeted plus regional biopsy
approach in prostate cancer diagnosis: a systematic review and meta-analysis. Eur Urol Open Sci.
2022;40:95–103.
51. Hu JC, Assel M, Allaf ME, Ehdaie B, Vickers AJ,
Cohen AJ, et al. Transperineal versus transrectal
magnetic resonance imaging–targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol.
2024;86:61.
52. Mian BM, Feustel PJ, Aziz A, Kaufman RP Jr,
Bernstein A, Avulova S, Fisher HAG.Complications
following transrectal and transperineal prostate
biopsy: results of the ProBE-PC randomized clinical
trial. J Urol. 2024;211(2):205–13.
53. Brant A, Campi R, Carrion DM, Esperto F, Sze C,
Johnson JP, et al. Findings from an international
survey of urology trainee experience with prostate
biopsy. BJU Int. 2023;131(6):705–11.
54. Giganti F, Kirkham A, Kasivisvanathan V, Papoutsaki
M-V, Punwani S, Emberton M, et al. Understanding
PI-QUAL for prostate MRI quality: a practical primer
for radiologists. Insights Imaging. 2021;12(1):59.
55. Sonn GA, Fan RE, Ghanouni P, Wang NN, Brooks
JD, Loening AM, etal. Prostate magnetic resonance
imaging interpretation varies substantially across
radiologists. Eur Urol Focus. 2019;5(4):592–9.
56. Turkbey B, Choyke PL.PI-QUAL, a new system for
evaluating prostate magnetic resonance imaging quality: is beauty in the eye of the beholder? Eur Urol
Oncol. 2020;3(5):620–1.

Multiparametric Ultrasound
forProstate Imaging andTargeting
DerekChan andKathrynNightingale
16
Introduction
Ultrasound is a fast, safe, and portable modality
for imaging the prostate. Conventional B-mode
ultrasound images are formed by using a transducer to transmit ultrasound into the tissue and
then tracking the backscattered signal as it is
reected toward the transducer. These images
visualize differences in acoustic impedance,
which is affected by tissue’s density and speed of
sound [1]. However, B-mode ultrasound often
has low sensitivity and specicity for prostate
lesions, which can appear isoechoic with healthy
tissue [2]. Because of this, many ultrasoundbased imaging modalities have been developed
based on differences in tissue characteristics
between prostate cancer and benign tissue to
image and target prostate cancer more
effectively.
Multiparametric ultrasound (mpUS) combines different ultrasound modalities to improve
imaging performance. Because each modality
has distinct advantages and challenges, and different ultrasound modalities may capture different characteristics of prostate cancer, it can be
benecial to combine information from multiple
modalities [3]. There have been many studies
D. Chan · K. Nightingale (*)
Department of Biomedical Engineering, Duke
University, Durham, NC, USA
e-mail: derek.chan@duke.edu; Kathy.nightingale@
duke.edu
investigating various combinations of ultrasound
imaging techniques [3–8].
The following sections include overviews of
ultrasound elastography (strain elastography,
shear wave elastography, and acoustic radiation
force impulse imaging), quantitative ultrasound,
Doppler and contrast-enhanced ultrasound, and
micro-ultrasound imaging, any of which can be
combined to generate multiparametric prostate
ultrasound images providing enhanced lesion
contrast.
Ultrasound Elastography
Elastography is the generation of images that
enable the assessment of tissue stiffness. It is
used in many clinical applications because tissue
elasticity often changes with disease state [9].
Elasticity has been studied as a biomarker in the
prostate because prostate cancer has been shown
to be stiffer than healthy tissue, possibly due to
an increase in collagen deposition and/or an
increase in cellular density and connectivity [9,
10]. This section contains an overview of three
elastography methods that have been applied in
the prostate: strain elastography, shear wave elastography, and acoustic radiation force impulse
(ARFI) imaging.
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
T. J. Polascik et al. (eds.), Imaging and Focal Therapy of Early Prostate Cancer,
https://doi.org/10.1007/978-3-031-66754-1_16
169

170
D. Chan and K. Nightingale
Strain Elastography
In strain elastography, the clinician applies slight
compression to the prostate using the ultrasound
transducer, and imaging data are acquired before
and during the compression [11]. A motiontracking algorithm is used to track the strain
induced in different regions of the prostate;
stiffer tissue will exhibit smaller displacement
and lower strains than softer tissue [12].
Figure16.1, reproduced from Yoo etal. (2012),
shows a strain elastography image and a grayscale B-mode image of the prostate, with the letter “A” in each image indicating a lesion with
increased stiffness [13].
Kanagaraju et al. (2020) conducted a study
with 60 patients. They found that strain elastography increased sensitivity to prostate cancer compared to B-mode ultrasound (89% vs. 79%),
though it was less specic than B-mode (56% vs.
Fig. 16.1 Strain elastography of the prostate, depicting
the strain ratio metric. (Reproduced from [13]: Yo o etal.
(2012), “Role of the elastography strain ratio using transrectal ultrasonography in the diagnosis of prostate cancer
and clinically signicant prostate cancer,” published in
Scientic Reports under a Creative Commons Attribution
4.0 International license)

16 Multiparametric Ultrasound forProstate Imaging andTargeting
171
81%) [11]. Yo o etal. (2022) investigated the use
of the elastography strain ratio for predicting
prostate cancer. They reported an area under the
receiver operative curve (AUC) of 0.845 when
the strain ratio was combined with variables such
as prostate-specic antigen (PSA) level and prostate volume [13].
Challenges with strain elastography include
imaging artifacts resulting from uneven compression or calcications, difculty quantifying the
elastic modulus because the applied stress is
generally unknown, and susceptibility to tissue
slip boundaries [14].
Shear Wave Elastography
Shear wave elastography is a quantitative imaging technique in which a focused ultrasound excitation is used to displace the tissue by several
microns, and the speed of the resulting shear
waves is estimated. If the tissue is assumed to be
linear, elastic, isotropic, and incompressible, then
the shear wave speed can be related to Young’s
modulus and shear modulus of the tissue, which
are elastic material constants related to tissue
stiffness [15]. A higher shear wave speed corresponds to stiffer tissue [16].
Because the elastic modulus obtained with
shear wave elastography is a quantitative metric
of tissue stiffness, it can be used to characterize
prostate tissue and establish a threshold to distinguish cancer from healthy tissue [16]. Figure16.2,
reproduced from Secasan etal. (2022), shows the
application of shear wave elastography in the
prostate; the shear modulus values are shown as a
color overlay on the grayscale B-mode image. In
the gure, the red region of the prostate is a
region with increased stiffness that was conrmed to be cancer after a biopsy [17].
A 2019 meta-analysis of shear wave elastography for detecting prostate cancer reported a
Fig. 16.2 Shear wave elastography in the prostate, shown
as the color overlay on the grayscale B-mode image. A
stiffer region of the prostate is shown in red. (Reproduced
from [17]: Secasan et al. (2022), “Articial Intelligence
System for Predicting Prostate Cancer Lesions from Shear
Wave Elastography Measurements,” published in Current
Oncology under a Creative Commons Attribution 4.0
license)
Соседние файлы в папке Библиотека им академика М.И. Перельмана
